SignatureFD’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.7K Buy
168
+1
+0.6% +$115 ﹤0.01% 2450
2026
Q2
$19.1K Buy
167
+5
+3% +$430 ﹤0.01% 2364
2026
Q1
$13.5K Buy
162
+22
+16% +$1.74K ﹤0.01% 2381
2025
Q4
$10.9K Hold
140
– – ﹤0.01% 2394
2025
Q3
$7.92K Hold
140
– – ﹤0.01% 2493
2025
Q2
$6.11K Buy
140
+65
+87% +$2.24K ﹤0.01% 2533
2025
Q1
$2.05K Buy
75
+16
+27% +$583 ﹤0.01% 2863
2024
Q4
$2.37K Hold
59
– – ﹤0.01% 2820
2024
Q3
$2.79K Hold
59
– – ﹤0.01% 2735
2024
Q2
$1.76K Hold
59
– – ﹤0.01% 2790
2024
Q1
$2.37K Hold
59
– – ﹤0.01% 2759
2023
Q4
$1.5K Buy
+59
New +$1.06K ﹤0.01% 2833
2023
Q3
– Sell
-31
Closed -$713 – 3258
2023
Q2
$713 Buy
31
+12
+63% +$344 ﹤0.01% 3031
2023
Q1
$563 Buy
+19
New +$613 ﹤0.01% 3083
2022
Q1
– Sell
-16
Closed -$1K – 3239
2021
Q4
$1K Buy
+16
New +$932 ﹤0.01% 2943
2021
Q3
– Sell
-16
Closed -$1K – 3135
2021
Q2
$1K Buy
+16
New +$695 ﹤0.01% 2755

Other funds holding KYMR

SignatureFD's KYMR Position: Q3 2026 in Review

SignatureFD increased its Kymera Therapeutics (KYMR) stake by 0.6% in Q3 2026, buying an estimated $115 and bringing the position to 168 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

SignatureFD first reported a position in KYMR in Q2 2021 and has held it in 16 quarters since. The position peaked at $19.1K in Q2 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • SignatureFD held 168 shares of Kymera Therapeutics worth $18.7K as of Q3 2026.
  • SignatureFD bought 1 Kymera Therapeutics share in Q3 2026, an estimated $115.
  • Kymera Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2450 holding.
  • SignatureFD first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • SignatureFD's Kymera Therapeutics position peaked at $19.1K in Q2 2026.
  • 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.